[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2008138592A1 - Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses - Google Patents

Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses Download PDF

Info

Publication number
WO2008138592A1
WO2008138592A1 PCT/EP2008/003839 EP2008003839W WO2008138592A1 WO 2008138592 A1 WO2008138592 A1 WO 2008138592A1 EP 2008003839 W EP2008003839 W EP 2008003839W WO 2008138592 A1 WO2008138592 A1 WO 2008138592A1
Authority
WO
WIPO (PCT)
Prior art keywords
halogen
alkyl
cycloalkyl
optionally substituted
groups selected
Prior art date
Application number
PCT/EP2008/003839
Other languages
French (fr)
Inventor
Richard John Davenport
Andrew James Ratcliffe
Mark William Jone
Original Assignee
Ucb Pharma, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0709218A external-priority patent/GB0709218D0/en
Application filed by Ucb Pharma, S.A. filed Critical Ucb Pharma, S.A.
Publication of WO2008138592A1 publication Critical patent/WO2008138592A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention concerns bicyclic and heterocyclic derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
  • the integrin ⁇ 4 is predominantly expressed on eosinophils, T and B lymphocytes, monocytes and basophils. It binds primarily to the vascular cell surface adhesion molecule VCAM-1 that is expressed on endothelium in response to inflammatory cytokines (TNF- ⁇ , IL-1 and selectively IL-4 and IL-13), extracellular matrix protein fibronectin and a cell surface adhesion molecule MAdCAM-1 that is expressed preferentially in the gastrointestinal track.
  • ⁇ 4 is not expressed on circulating neutrophils, which are the first defence against infection, it is a target for the pharmacological control of inflammatory diseases.
  • Diseases include asthma, multiple sclerosis (MS), rheumatoid arthritis (RA) or inflammatory bowel diseases.
  • ⁇ 4 is also expressed on leukemic cells that show increased survival through binding to fibronectin expressed on bone marrow stormal cells. Blocking this interaction in the presence of chemotherapy is beneficial in preventing relapse of acute myelogenous leukemia.
  • ⁇ 4 and VCAM-1 have also been identified in smooth muscle cells from intimal atherosclerotic thickening of adult aorta. Blocking this interaction is beneficial in preventing smooth muscle differentiation and atherosclerosis.
  • lung e.g. non-small cell lung, pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer.
  • the invention therefore provides a compound having formula I, its enantiomers, diastereoisomers or a pharmaceutically acceptable salt thereof,
  • X is CH or N
  • W is CH or N
  • R is chlorine or methoxy
  • R 1 is chlorine or methoxy
  • Y 1 is CH, N, CR 3 , CR 10 Or CR 17 ;
  • Y 2 is CH, N, CR 3 , CR 10 or CR 17 ;
  • Y 3 is CH, N, CR 3 , CR 1 ° or CR 17 ;
  • Y 4 is CH, N, CR 3 , CR 10 or CR 17 ;
  • Y 5 is CH, N, CR 3 , CR 1 ° or CR 17 ;
  • R 2 is Ci_6 alkyl;
  • R 3 is R 4 Or -G 1 R 5 ;
  • R 4 is C 1 . e alkyl optionally substituted by groups selected from halogen, C ⁇ .-io cycloalkyl, amino, C- ⁇ alkylamino, C- ⁇ dialkylamino, C6--
  • R5 is hydrogen; or is C-
  • R? is hydrogen; or is C-] .
  • ⁇ alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C-
  • R8 is hydrogen; or is C-
  • m is O to 3;
  • R 1 1 is C-
  • R14 is hydrogen; or is C-
  • R15 j hydrogen; or is C-
  • R16 is hydrogen; or is C-
  • R 17 is R 18 Or -G 3 R 19 ;
  • ⁇ alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C- ⁇ g alkylamino, C-
  • R19 is hydrogen; or is C-
  • alkylsulfones C ⁇ .Q alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C- ⁇ alkyl, halogen, C- ⁇ g alkylamino, C ⁇ _Q dialkylamino, C3.10 cycloalkyl;
  • R20 j s hydrogen; or is C-
  • R21 is hydrogen; or is C-
  • R22 j hydrogen; or is C-
  • R23 is hydrogen; or is C-
  • the invention therefore provides a compound having formula Ia, and the configuration at the asymmetric carbon atom is in the "S" configuration or a pharmaceutically acceptable salt thereof,
  • C-] _6 alkyl represents saturated, monovalent hydrocarbon radicals having linear or branched moieties or combinations thereof and containing 1-6 carbon atoms.
  • One methylene (-CH2-) group, of the alkyl, can be replaced by oxygen or sulfur.
  • Alkyl moieties can be optionally substituted by halogen, C3.10 cycloalkyl, amino, C-] _ ⁇ alkylamino, C-
  • alkyl group in the present case, is methyl.
  • C3.10 cycloalkyl refers to a monovalent or divalent group of 3 to 10 carbon atoms, derived from a saturated cyclic hydrocarbon. Cycloalkyl groups can be mono- or polycyclic. Cycloalkyl groups can be optionally substituted by halogen or C ⁇
  • C2-6 alkenyl represents a 2-6 carbon atom chain as defined above, having an unsaturated bond.
  • cyano refers to a group of formula -CN.
  • nitro refers to a group of formula -NO2.
  • amino refers to a group of formula -NH2.
  • carboxylic acid refers to a group of formula -COOH.
  • halogen refers to an atom of chlorine, bromine, fluorine, iodine. Usually halogen is chlorine.
  • C ⁇ -io ar y' refers to an organic moiety derived from an aromatic hydrocarbon consisting of a ring or multiple rings, containing 6 to 10 carbon atoms by removal of one hydrogen atom, which can optionally be substituted by amino, C-
  • Q heteroaryl refers to a 6 -10 member ring, containing at least one nitrogen atom interrupting the carbocyclic ring structure.
  • the 6 member aromatic heterocycles can be optionally substituted by C- ⁇ alkyl, C2-6 alkenyl, halogen, C- ⁇ alkylamino, C- ⁇ g dialkylamino, C-
  • 3-10 ring member non-aromatic heterocycle refers to a 3 to 10 ring member, containing one N or O heteroatom interrupting the carbocyclic ring structure.
  • the 3-10 ring member non-aromatic heterocycle can be optionally substituted by groups selected from C-) .Q alkyl, halogen, C-
  • C- ⁇ alkyloxy refers, to a refers to a group of formula - OR a , wherein R a is a C-
  • C-] _Q alkylsulfides refers to a group of formula -SRb, wherein R ⁇ is a C- ⁇ alkyl group as defined above.
  • C- ⁇ alkylsulfones refers to a group of formula -
  • R c is a C-
  • C-] .Q alkylsulfoxides refers to a group of formula - is a C-
  • -6 alkylamino refers to a group of formula -NHR n , wherein R n is a C ⁇
  • _6 dialkylamino refers to a group of formula -NR'RJ, wherein R' is a C-
  • X is CH or N. Usually X is CH. Generally W is CH or N. Usually W is N.
  • R ⁇ is chlorine or methoxy. Usually R ⁇ is chlorine.
  • R is chlorine or methoxy. Usually R is chlorine.
  • Y 1 is CH, N, CR 3 , CR 10 or CR 17 .
  • Y 1 is CH.
  • Y 2 is CH, N, CR 3 , CR 10 or CR 17 .
  • Y 2 is CH.
  • Y 3 is CH, N, CR 3 , CR 10 or CR 17 .
  • Y 3 is CH.
  • Y 4 is CH, N, CR 3 , CR 10 or CR 17 .
  • Y 4 is CH.
  • Y 5 is CH, N, CR 3 , CR 10 or CR 17 .
  • Y 5 is CH.
  • n 0 to 3. Usually n is 0.
  • R 2 is C-
  • R 4 is C- ⁇ alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-) _Q alkylamino, C- ⁇ g dialkylamino, Cg-io ar y' > cyano, nitro; or is C 2 -6 alkenyl; or is halogen; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-
  • R ⁇ is hydrogen; or is C-
  • R ⁇ is hydrogen; or is C ⁇
  • R 7 is hydrogen; or is C-
  • R ⁇ is hydrogen; or is C-
  • R ⁇ is hydrogen; or is C-
  • Q aryi, cyano, nitro or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-
  • R 10 is R 1 1 or -G 2 R 12 -
  • n O to 3.
  • n O.
  • R 1 1 is C- ⁇ g alkyl optionally substituted by groups selected from halogen,
  • R 12 is hydrogen; or is C-
  • R ⁇ 4 is hydrogen; or is C-
  • R 1 7 is R 18 or -G 3 R 19 .
  • o is O to 3. Usually o is O.
  • R 18 is C-
  • R ⁇ is hydrogen; or is C-) .5 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C- ⁇ .Q alkylamino, C- ⁇ g dialkylamino, Cg.10 ar yl > cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-
  • R21 is hydrogen; or is Ci_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C- ⁇ alkylamino, C-
  • R ⁇ 3 is hydrogen; or is C-
  • X is CH; and W is N; and R ⁇ is chlorine; and R is chlorine; and R 2 is C ⁇ _Q alkyl; and n is 0; and m is 0; and o is 0; and Y 1 is CH; and Y 2 is CH; and Y 3 is CH; and Y 4 is CH and Y 5 is CH.
  • stereogenic centre in their structure.
  • This stereogenic centre may be present in "R” or "S” configuration, said “R” and “S” notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-30.
  • the asymmetric carbon atom is preferably in the "S" configuration.
  • the "pharmaceutically acceptable salts" according to the invention include therapeutically active, non-toxic base and acid salt forms which the compounds of formula I are able to form.
  • the acid addition salt form of a compound of formula I that occurs in its free form as a base can be obtained by treating the free base with an appropriate acid such as an inorganic acid, for example, a hydrohalic such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and the like; or an organic acid, such as, for example, acetic, hydroxyacetic, propanoic, lactic, pyruvic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p- aminosalicylic, pamoic, formic and the like (Handbook of Pharmaceutical Salts, P. Heinrich Stahl
  • the compounds of formula I containing acidic protons may be converted into their therapeutically active, non-toxic base addition salt forms, e.g. metal or amine salts, by treatment with appropriate organic and inorganic bases.
  • Appropriate base salt forms include, for example, ammonium salts, alkali and earth alkaline metal salts, e.g. lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. N-methyl-D-glucamine salts, and salts with amino acids such as, for example, arginine, lysine and the like (Handbook of Pharmaceutical Salts, P. Heinrich Stahl & Camille G. Wermuth (Eds), Verlag Helvetica Chimica Acta - Zurich, 2002, 329-345).
  • said salt forms can be converted into the free forms by treatment with an appropriate base or acid.
  • solvates include for example hydrates, alcoholates and the like.
  • the invention also relates to all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds of formula I or mixtures thereof (including all possible mixtures of stereoisomers).
  • resolution of the mixture of stereoisomers can best be effected in one or several steps, involving generally sequential separation of mixtures of diastereomers into their constituting racemates, using preferably chromatographic separations on achiral or chiral phase in reversed or preferably in direct mode, followed by at least one ultimate step of resolution of each racemate into its enantiomers, using most preferably chromatographic separation on chiral phase in reversed or preferably in direct mode.
  • the ultimate step may be a separation of diastereomers using preferably chromatographic separations on achiral or chiral phase in reversed or preferably in direct mode.
  • the compounds according to the invention are useful for the treatment of asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, ⁇ 4-related cancers such as lung e.g.
  • non-small cell lung pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer.
  • the present invention in a further aspect, concerns the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of disorders such as mentioned above.
  • the present invention concerns the use of a compound of formula I or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of ⁇ 4 dependent inflammatory or medical conditions such as for example asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, oc4-related cancers such as lung e.g.
  • ⁇ 4 dependent inflammatory or medical conditions such as for example asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, r
  • non-small cell lung pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer.
  • the compounds of the invention are useful for treating conditions mediated by adhesion mechanisms. These conditions include asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, ⁇ 4-related cancers such as lung e.g.
  • non-small cell lung pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer.
  • Subjects in need of treatment for a ⁇ 4 dependent inflammatory or medical condition asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, ⁇ 4-related cancers such as lung e.g.
  • non-small cell lung pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer, can be treated by administering to the patient an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable derivative or salt thereof in a pharmaceutically acceptable carrier or diluent to reduce formation of oxygen radicals.
  • the active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermal ⁇ , subcutaneously, intramuscularly or topically, in liquid, cream, gel or solid form, via a buccal or nasal spray, or aerosol, a patch or suppositories.
  • the invention further concerns the use of the compounds of formula I for the manufacture of a medicament for therapeutic application.
  • the invention concerns the use of the compounds of formula I for the manufacture of a medicament useful for treating conditions in which there is likely to be a ⁇ 4 dependent component.
  • the invention concerns the use of the compound of formula I for the manufacture of a medicament useful for treating asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, ⁇ 4-related cancers such as lung e.g.
  • non-small cell lung pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer.
  • the invention further concerns the compounds of formula I for use as medicaments.
  • the invention concerns the compounds of formula I for use as a medicament for treating asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, ⁇ 4-related cancers such as lung e.g.
  • non-small cell lung pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer.
  • the activity and properties of the active compounds, oral availability and stability in vitro or in vivo can vary significantly among the optical isomers of the disclosed compounds.
  • the active compound is administered in an enantiomerically enriched form, i.e., substantially in the form of one isomer.
  • the present invention also concerns a method for treating ⁇ 4 dependent inflammatory or medical condition (preferably asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, ⁇ 4-related cancers such as lung e.g.
  • ⁇ 4 dependent inflammatory or medical condition preferably asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple s
  • non-small cell lung pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer) in a mammal in need of such treatment, comprising administering a therapeutic dose of at least one compound of formula I or a pharmaceutically acceptable salt thereof to a patient.
  • the methods of the invention comprise administration to a mammal (preferably human) suffering from above mentioned conditions or disorders, of a compound according to the invention in an amount sufficient to alleviate or prevent the disorder or condition.
  • the compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing 0.01 to 2000 mg, preferably 0.05 to 500 mg of active ingredient per unit dosage form.
  • treatment includes curative treatment and prophylactic treatment.
  • substantially refers to a composition of equal or higher than 85% of one isomer, usually 90 % and preferably 95%.
  • curative is meant efficacy in treating a current symptomatic episode of a disorder or condition.
  • prophylactic is meant prevention of the occurrence or recurrence of a disorder or condition.
  • the compounds are of use in modulating cell adhesion and in particular are of use in the prophylaxis and treatment of diseases or disorders in which the extravasation of leukocytes plays a role and the invention extends to such a use and to the use of the compounds for the manufacture of a medicament for treating such diseases or disorders.
  • Diseases or disorders of this type include inflammatory arthritis such as rheumatoid arthritis, vasculitis or polydermatomyositis, multiple sclerosis, transplantation, diabetes, inflammatory dermatoses such as psoriasis or dermatitis, asthma and inflammatory bowel disease.
  • One aspect of the invention includes methods for treating ⁇ 4-related cancers
  • cancers including cancers, whether solid or haematopoietic.
  • cancers include, but are not limited to, lung e.g. non-small cell lung, pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer. Results obtained with compounds of formula I are indicative of a strong pharmacological effect.
  • compounds of formula I or their pharmaceutically acceptable salts may be employed at an effective daily dosage and administered in the form of a pharmaceutical composition. Therefore, another embodiment of the present invention concerns a pharmaceutical composition comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable diluent or carrier.
  • one or more of the compounds of formula I or a pharmaceutically acceptable salt thereof is intimately admixed with a pharmaceutical diluent or carrier according to conventional pharmaceutical compounding techniques known to the skilled practitioner.
  • compositions comprising compounds according to the invention can, for example, be administered orally or parenterally, i.e., intravenously, intramuscularly, subcutaneously or intrathecally.
  • compositions suitable for oral administration can be solids or liquids and can, for example, be in the form of tablets, pills, dragees, gelatine capsules, solutions, syrups, and the like.
  • the active ingredient may be mixed with an inert diluent or a non-toxic pharmaceutically acceptable carrier such as starch or lactose.
  • these pharmaceutical compositions can also contain a binder such as microcrystalline cellulose, gum tragacanth or gelatine, a disintegrant such as alginic acid, a lubricant such as magnesium stearate, a glidant such as colloidal silicon dioxide, a sweetener such as sucrose or saccharin, or colouring agents or a flavouring agent such as peppermint or methyl salicylate.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatine
  • a disintegrant such as alginic acid
  • a lubricant such as magnesium stearate
  • a glidant such as colloidal silicon dioxide
  • a sweetener such as sucrose or saccharin
  • colouring agents or a flavouring agent such as peppermint or methyl salicylate.
  • compositions which can release the active substance in a controlled manner are in conventional form such as aqueous or oily solutions or suspensions generally contained in ampoules, disposable syringes, glass or plastics vials or infusion containers.
  • these solutions or suspensions can optionally also contain a sterile diluent such as water for injection, a physiological saline solution, oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents, antibacterial agents such as benzyl alcohol, antioxidants such as ascorbic acid or sodium bisulphite, chelating agents such as ethylene diamine-tetra-acetic acid, buffers such as acetates, citrates or phosphates and agents for adjusting the osmolarity, such as sodium chloride or dextrose.
  • a sterile diluent such as water for injection, a physiological saline solution, oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents, antibacterial agents such as benzyl alcohol, antioxidants such as ascorbic acid or sodium bisulphite, chelating agents such as ethylene diamine-tetra-acetic acid, buffers such as acetates, citrate
  • the amount of active ingredient in the pharmaceutical compositions can fall within a wide range of concentrations and depends on a variety of factors such as the patient's sex, age, weight and medical condition, as well as on the method of administration.
  • the quantity of compound of formula I in compositions for oral administration is at least 0.5 % by weight and can be up to 80 % by weight with respect to the total weight of the composition.
  • the daily dosage is in the range 0.01 to 2000 milligrams (mg) of compounds of formula I.
  • the quantity of compound of formula I present is at least 0.5 % by weight and can be up to 33 % by weight with respect to the total weight of the composition.
  • the dosage unit is in the range 0.01 mg to 2000 mg of compounds of formula I.
  • the daily dose can fall within a wide range of dosage units of compound of formula I and is generally in the range 0.01 to 2000 mg. However, it should be understood that the specific doses could be adapted to particular cases depending on the individual requirements, at the physician's discretion.
  • the compounds of the invention may be co-administered with another therapeutic agent most likely from a different therapeutic area.
  • Co-administration in this context means the dosing either of components, which are formulated together as a single dosage form; or the administration of separately formulated agents at substantially the same time, or sequential dosing of a compound of the invention followed by a therapeutic agent of a different therapeutic area.
  • suitable examples of therapeutic agents may include, but are not limited to, histamine H1 antagonists such as cetirizine, histamine H2 antagonists, histamine H3 antagonists, leukotriene antagonists, PDE4 inhibitors such as 3-cyclo- propylmethoxy-4-difluoromethoxy- ⁇ /-[3,5-di-chloropyrid-4-yl]-benzamide, muscarinic M3 antagonists, ⁇ 2 agonists, theophylline, sodium cromoglycate, anti-TNF antibodies such as certolizumab pegol or adalimumab, anti-IL6 antibodies, anti-IL17 antibodies, adhesion molecule inhibitors, inhibitors of cytokine synthesis such as P38 MAP kinase inhibitors and inhibitors of PI3 kinase, methotrexate.
  • histamine H1 antagonists such as cetirizine
  • histamine H2 antagonists histamine H3 antagonists
  • the present invention concerns also processes for preparing the compounds of formula I.
  • the compounds of formula I according to the invention can be prepared analogously to conventional methods as understood by the person skilled in the art of synthetic organic chemistry.
  • the present invention also relates to synthetic intermediates geometrical isomers, enantiomers, diastereoisomers, pharmaceutically acceptable salts and all possible mixtures thereof.
  • characterization of the compounds is performed according to (LCMS) liquid chromatography mass spectra, preparative liquid chromatography LC, NMR, and silica gel chromatography methods. NMR spectra are recorded on Bruker AV300 and DRX 400 spectrometers at 300 and 400 MHz respectively. Chromatographic separations are performed on Davis 5 ⁇ M silica gel.
  • the Waters mass spectrometers used are of model ZMD or ZQ both Waters.
  • NMR spectra are recorded on a Bruker AV-300 or DRX-400 Spectrometers operating at 300.13 MHz or 400.13 MHz for protons, and running the Bruker XWINNMR software package. Spectra are acquired at room temperature unless otherwise stated. Chemical shifts are given in ppm referenced either to internal TMS or to the residual solvent signal.
  • Example 2 The following protein assay is used to demonstrate the potency of the compounds according to the invention. In this assay an IC50 value is determined for each test compound and represents the concentration of compound necessary to achieve 50% inhibition of binding VCAM-mFc / a4b1-hFc protein binding assay in DELFIA format.
  • test compound IC50 values calculated.
  • (2S)-3-[2-(2,6-dichlorophenyl)quinolin-6-yl]-2- ⁇ [methyl(phenyl)carbamoyl]amino ⁇ propanoic acid has an activity between 30 and 50 nM in the above assay.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention concerns bicyclic and heterobicyclic derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

Description

BICYCLIC AND HETEROBICYCLIC DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES
The present invention concerns bicyclic and heterocyclic derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
The integrin α4 is predominantly expressed on eosinophils, T and B lymphocytes, monocytes and basophils. It binds primarily to the vascular cell surface adhesion molecule VCAM-1 that is expressed on endothelium in response to inflammatory cytokines (TNF-α, IL-1 and selectively IL-4 and IL-13), extracellular matrix protein fibronectin and a cell surface adhesion molecule MAdCAM-1 that is expressed preferentially in the gastrointestinal track.
Because α4 is not expressed on circulating neutrophils, which are the first defence against infection, it is a target for the pharmacological control of inflammatory diseases. Several in vitro and in vivo studies have indicated an important role of α4 in cell adhesion mediated inflammatory pathologies and that blocking its function is beneficial. Diseases include asthma, multiple sclerosis (MS), rheumatoid arthritis (RA) or inflammatory bowel diseases. α4 is also expressed on leukemic cells that show increased survival through binding to fibronectin expressed on bone marrow stormal cells. Blocking this interaction in the presence of chemotherapy is beneficial in preventing relapse of acute myelogenous leukemia. α4 and VCAM-1 have also been identified in smooth muscle cells from intimal atherosclerotic thickening of adult aorta. Blocking this interaction is beneficial in preventing smooth muscle differentiation and atherosclerosis.
The interaction of α4 on inflammatory cells with fibronectin has also been shown to increase chronic allograft failure. Blocking this interaction is beneficial in supporting transplant survival. α4-has also been related to cancers (including cancers, whether solid or haematopoietic) but not limited to, lung e.g. non-small cell lung, pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer.
International patent application WO 03/093237 discloses 2,6-quinolinyl and 2,6- naphthyl derivatives as pharmaceuticals for the treatment of VLA-4 dependent inflammatory diseases. We have now found some bicyclic and heterobicyclic compounds that are potent inhibitors of α4 integrins and have good intestinal permeability.
In one aspect, the invention therefore provides a compound having formula I, its enantiomers, diastereoisomers or a pharmaceutically acceptable salt thereof,
Figure imgf000003_0001
R~
formula I wherein:
X is CH or N;
W is CH or N;
R is chlorine or methoxy;
R1 is chlorine or methoxy; Y1 is CH, N, CR3, CR10 Or CR17;
Y2 is CH, N, CR3, CR10 or CR17;
Y3 is CH, N, CR3, CR1 ° or CR17;
Y4 is CH, N, CR3, CR10 or CR17;
Y5 is CH, N, CR3, CR1 ° or CR17; R2 is Ci_6 alkyl;
R3 is R4 Or -G1 R5;
G1 is -O-, -C(O)-, -S-, -S=O, -S(O)2-, C(O)N(R6)-, -N(R7)C(O)- , -N(R8)S(O)2-
N(R9)-; n is O to 3; R4 is C1. e alkyl optionally substituted by groups selected from halogen, Cβ.-io cycloalkyl, amino, C-μβ alkylamino, C-μβ dialkylamino, C6--|o ary', cyano, nitro; or is C2-6 alkenyl; or is halogen; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-|_6 alkyl; or is Cø-10 aryl optionally substituted by groups selected from amino, C-μg alkylamino, C-μg dialkylamino, C-|_β alkyloxy, C-|_β alkylsulfides, C-|_β alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl, C-\.Q alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-|_g alkyl, C2-6 alkenyl, halogen, C-μg alkylamino, C-μg dialkylamino, C<|_6 alkyloxy, C<\.Q alkylsulfides, C-] .Q alkylsulfones, C-|_β alkylsulfoxides, 03.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-j_6 alkyl, halogen, C-|_β alkylamino, C-|_β dialkylamino, C3.10 cycloalkyl; or is hydroxyl; or is carboxylic acid; or is cyano; or is nitro;
R5 is hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-| .Q alkylamino, C-|_β dialkylamino, C5.10 aryl, cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-μg alkyl; or is Cβ-io ary' optionally substituted by groups selected from amino, C-|_6 alkylamino, C-μø dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-|_6 alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl, C-|_6 alkyl, halogen; or is Cg.10 heteroaryl optionally substituted by groups selected from C-μg alkyl,
C2-6 alkenyl, halogen, C-μg alkylamino, C-|.ρ dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-|_β alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_β alkyl, halogen, C-|_6 alkylamino, C-μg dialkylamino, C3.10 cycloalkyl; R6 is hydrogen; or is C<|_6 alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C-|_6 alkylamino, C-|_6 dialkylamino, C6-10 aryl. cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-) _Q alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-|_g alkylamino, C-μβ dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-|_6 alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl, C-|.β alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-|_6 alkylamino, C-|_6 dialkylamino, C-|_β alkyloxy, C-μg alkylsulfides, Ci_6 alkylsulfones, C-\ .Q alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-j.β alkyl, halogen, C-μg alkylamino, C-|_6 dialkylamino, C3.10 cycloalkyl;
R? is hydrogen; or is C-] . β alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C-|_6 alkylamino, C-|_6 dialkylamino, Cg-io ary'> cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-μβ alkyl; or is Cβ-10 aryl optionally substituted by groups selected from amino, C-\.Q alkylamino, C-i.g dialkylamino, C<|_6 alkyloxy, C-|_6 alkylsulfides, C-|_6 alkylsulfones, C-i_6 alkylsulfoxides, C3.-10 cycloalkyl, Ci_6 alkyl, halogen; or is Cg.10 heteroaryl optionally substituted by groups selected from C-|_6 alkyl, C2-6 alkenyl, halogen, C-μg alkylamino, C-μg dialkylamino, C^.g alkyloxy, C-|_6 alkylsulfides, C-| _Q alkylsulfones, C-μg alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_6 alkyl, halogen, C-|_g alkylamino, C^.g dialkylamino, C3.10 cycloalkyl;
R8 is hydrogen; or is C-| . β alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-μg alkylamino, C-\.Q dialkylamino, C5.10 ary'> cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C^ .5 alkyl; or is Cβ_-| rj aryl optionally substituted by groups selected from amino, C-|_6 alkylamino, C-\ .Q dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-|.β alkylsulfones, C1.5 alkylsulfoxides, C3.10 cycloalkyl, C-|_6 alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-|_e alkyl,
C2-6 alkenyl, halogen, C-|_6 alkylamino, C-1.5 dialkylamino, C-|_6 alkyloxy, C-|.β alkylsulfides, C-|_6 alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_6 alkyl, halogen, Ci_6 alkylamino, C-|_6 dialkylamino, C3.10 cycloalkyl; F?9 is hydrogen; or is C-| .6 alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C-] _β alkylamino, C<|_6 dialkylamino, Cβ-io aryl, cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-|_6 alkyl; or is Cβ-10 aryl optionally substituted by groups selected from amino, C^.Q alkylamino, C-|_6 dialkylamino, C-|.β alkyloxy, C-|_6 alkylsulfides, C-μβ alkylsulfones, C-|_β alkylsulfoxides, C3.10 cycloalkyl, C-|_β alkyl, halogen; or is Cβ-10 heteroaryl optionally substituted by groups selected from C-μø alkyl, C2-6 alkenyl, halogen, C-|_6 alkylamino, C-\ .Q dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, Ci_6 alkylsulfones, C-|_g alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-μβ alkyl, halogen, C-|.β alkylamino, C^.Q dialkylamino, C3.10 cycloalkyl;
R1O iS R1 1 Or -G2R12;
G2 is -O-, -C(O)-, -S-, -S=O, -S(O)2-, C(O)N(R1S)-, -N(R14)C(O)- , -N(R15)S(O)2-, - N(R16)-; m is O to 3;
R1 1 is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-μβ alkylamino, C-|.g dialkylamino, Cβ-io aryl, cyano, nitro; or is C2_6 alkenyl; or is halogen; or is C3..-10 cycloalkyl optionally substituted by groups selected from halogen, C-] _Q alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-μβ alkylamino, C-|.β dialkylamino, C-μβ alkyloxy, C-|_6 alkylsulfides, C-|_g alkylsulfones, C1.5 alkylsulfoxides, C3.10 cycloalkyl, C-] .Q alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-| _Q alkyl, C2-6 alkenyl, halogen, C-j.g alkylamino, C-|_6 dialkylamino, C-|.β alkyloxy, C-j.β alkylsulfides, C-|_6 alkylsulfones, C-\.Q alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C<|_6 alkyl, halogen, C-|.β alkylamino, Ci_β dialkylamino, 03.10 cycloalkyl; or is hydroxy I; or is carboxylic acid; or is cyano; or is nitro; R12 is hydrogen; or is C-| _ β alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C-|_g alkylamino, C-μg dialkylamino, Cg. -| Q ary'. cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|_g alkyl; or is C6-10 aryl optionally substituted by groups selected from amino, C-|_g alkylamino, C-μg dialkylamino, C-μg alkyloxy, C-|_g alkylsulfides, C-|_g alkylsulfones, C-|_g alkylsulfoxides, C3.10 cycloalkyl, C-|_6 alkyl, halogen; or is Cg-io heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-μg alkylamino, C-μg dialkylamino, C-|_g alkyloxy, C-] _g alkylsulfides, C-|_g alkylsulfones, C-|_g alkylsulfoxides, C3.-10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_g alkyl, halogen, C-|_g alkylamino, C-|.g dialkylamino, C3.10 cycloalkyl;
R13 js hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-μg alkylamino, C-|_g dialkylamino, Cg.-) Q aryl, cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-] _g alkyl; or is Cg_io aryl optionally substituted by groups selected from amino, C-|.g alkylamino, C-|.g dialkylamino, C-j.g alkyloxy, C-μg alkylsulfides, C-|_g alkylsulfones, C-|.g alkylsulfoxides, C3.10 cycloalkyl, C-|.g alkyl, halogen; or is Cg_-|o heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-g alkenyl, halogen, C-|.g alkylamino, C-μg dialkylamino, C-|_g alkyloxy, Ci_g alkylsulfides, C-i_g alkylsulfones, C-|.g alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|.g alkyl, halogen, Ci_g alkylamino, C-|.g dialkylamino, C3.10 cycloalkyl;
R14 is hydrogen; or is C-|.g alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-μg alkylamino, C-|_g dialkylamino, Cg.10 aryl, cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|_g alkyl; or is Cg.10 aryl optionally substituted by groups selected from amino, C-μg alkylamino, C-μg dialkylamino, C-|.g alkyloxy, C-μg alkylsulfides, C-|.g alkylsulfones, C-j.g alkylsulfoxides, C3-10 cycloalkyl, C-μg alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μø a'M> C2-6 alkenyl, halogen, C-μβ alkylamino, C-|_6 dialkylamino, C-|_6 alkyloxy, C1.5 alkylsulfides, C^.Q alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C^.β alkyl, halogen, C<\_Q alkylamino, C-μø dialkylamino, C3.10 cycloalkyl;
R15 js hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-|.β alkylamino, C-] .5 dialkylamino, Cβ-io ary'- cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-|_6 alkyl; or is Cβ-io ary' optionally substituted by groups selected from amino, C-μβ alkylamino, C-μø dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-μø alkylsulfones, C-|.β alkylsulfoxides, C3.-10 cycloalkyl, C-|.β alkyl, halogen; or is Cβ-10 heteroaryl optionally substituted by groups selected from C-μβ alkyl, C2-6 alkenyl, halogen, C<[ .Q alkylamino, C-|_β dialkylamino, C-|_6 alkyloxy, C<|_6 alkylsulfides, C-μg alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|.β alkyl, halogen, C-|.β alkylamino, C-|_6 dialkylamino, C3.10 cycloalkyl;
R16 is hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.1 rj cycloalkyl, amino, C1-6 alkylamino, C1-6 dialkylamino, Cg.10 ary1- cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|.β alkyl; or is Cβ-10 ary! optionally substituted by groups selected from amino, C1-6 alkylamino, C1-6 dialkylamino, C-|_6 alkyloxy, C-1.5 alkylsulfides, C-μg alkylsulfones, C-|.β alkylsulfoxides, C3-10 cycloalkyl, C1-6 alkyl, halogen; or is Cg-i 0 heteroaryl optionally substituted by groups selected from C-μβ alkyl,
C2-6 alkenyl, halogen, C-μg alkylamino, C-μg dialkylamino, C-|.β alkyloxy, C-μg alkylsulfides, C-|.ρ alkylsulfones, C-|.β alkylsulfoxides, C3.-10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-μβ alkyl, halogen, C-|.β alkylamino, C-|.β dialkylamino, C3.10 cycloalkyl;
R17 is R18 Or -G3R19;
G3 is -O-, -C(O)-, -S-, -S=O, -S(O)2-, C(O)N(R20)-, -N(R21)C(O)- , -N(R22JS(O)2-, -
N(R23)-; o is O to 3; R18 is C-]. β alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-μg alkylamino, C-|_β dialkylamino, Cg-io ary'- cyano, nitro; or is C2-6 alkenyl; or is halogen; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-μg alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-|_g alkylamino, C-μg dialkylamino, C-|.g alkyloxy, C-|_6 alkylsulfides, C-μρ alkylsulfones, C^.Q alkylsulfoxides, C3.10 cycloalkyl, C-|_6 alkyl, halogen; or is Cg-10 heteroaryl optionally substituted by groups selected from C-|.g alkyl,
C2-6 alkenyl, halogen, C-μg alkylamino, C-|_6 dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-|_6 alkylsulfones, C-|_β alkylsulfoxides, C3_I Q cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-μβ alkyl, halogen, C-μg alkylamino, C-|_6 dialkylamino, C3.10 cycloalkyl; or is hydroxyl; or is carboxylic acid; or is cyano; or is nitro;
R19 is hydrogen; or is C-|_6 a'M optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-1.5 alkylamino, C-|.β dialkylamino, Cβ_io ary'. cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-] _Q alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-μβ alkylamino, C-|.g dialkylamino, C-|_6 alkyloxy, C-|.β alkylsulfides, C-μβ alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl, C-|.β alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-] _Q alkyl, C2-6 alkenyl, halogen, C-|.β alkylamino, C-i.g dialkylamino, C-|_β alkyloxy, C-|_6 alkylsulfides, C-i.β alkylsulfones, C^ .Q alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-μβ alkyl, halogen, C-μg alkylamino, C<\ _Q dialkylamino, C3.10 cycloalkyl;
R20 js hydrogen; or is C-| . β alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C-μg alkylamino, C<|_6 dialkylamino, Cg-io aryl, cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-μg alkyl; or is CQ-10 aryl optionally substituted by groups selected from amino, C-|_g alkylamino, C-μg dialkylamino, C-|_g alkyloxy, C-μg alkylsulfides, C-μg alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl, C-|_6 alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-μg alkylamino, C-|_g dialkylamino, Ci_6 alkyloxy, C-μg alkylsulfides, C-μg alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_g alkyl, halogen, C-|_g alkylamino, C-|_g dialkylamino, C3.10 cycloalkyl;
R21 is hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-|_g alkylamino, C-|_6 dialkylamino, Cβ-io aryl, cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-j.g alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-μg alkylamino, C-μg dialkylamino, C<\_Q alkyloxy, Ci_g alkylsulfides, C-μg alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl, C-|_g alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C<|_6 alkylamino, C-|_6 dialkylamino, C-|_β alkyloxy, C-μβ alkylsulfides, C-i.β alkylsulfones, C-|.g alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-i.g alkyl, halogen, C-|_6 alkylamino, C<|_β dialkylamino, C3.10 cycloalkyl;
R22 js hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.1 rj cycloalkyl, amino, C-|.β alkylamino, C-|_6 dialkylamino, Cg.10 aryl. cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|_ Q alkyl; or is Cg.10 aryl optionally substituted by groups selected from amino, C-μg alkylamino, C-μg dialkylamino, C-|.g alkyloxy, C-|.g alkylsulfides, C-μg alkylsulfones, C-|.g alkylsulfoxides, C3.10 cycloalkyl, C-μg alkyl, halogen; or is Cg_io heteroaryl optionally substituted by groups selected from C-|_g alkyl, C2-g alkenyl, halogen, C-|.g alkylamino, C-μg dialkylamino, C-|.g alkyloxy, C-|.g alkylsulfides, C-).g alkylsulfones, C-|.g alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|.β alkyl, halogen, C-|_6 alkylamino, C-|.β dialkylamino, C3.10 cycloalkyl;
R23 is hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-μø alkylamino, C-|.β dialkylamino, Cβ-io ary'> cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-|_6 alkyl; or is Cβ-10 aryl optionally substituted by groups selected from amino, C-|_6 alkylamino, C-μρ dialkylamino, C-μβ alkyloxy, C-|.β alkylsulfides, C-|.β alkylsulfones, C1.5 alkylsulfoxides, C3.10 cycloalkyl, C-μβ alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-|_ Q alkyl, C2-6 alkenyl, halogen, C-μø alkylamino, C-|_6 dialkylamino, C-|.β alkyloxy, C-|_e alkylsulfides, C-|.β alkylsulfones, C-μe alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_β alkyl, halogen, C<|_6 alkylamino, C-|.β dialkylamino, C3.-10 cycloalkyl.
In another aspect, the invention therefore provides a compound having formula Ia, and the configuration at the asymmetric carbon atom is in the "S" configuration or a pharmaceutically acceptable salt thereof,
Figure imgf000011_0001
formula Ia wherein:
X 1 W 1 R, R1 . Y1 . Y2, γ3, γ4_ γ5 _ R2_ R3 _ R10 R17 are defined as above. The term "C-] _6 alkyl", as used herein, represents saturated, monovalent hydrocarbon radicals having linear or branched moieties or combinations thereof and containing 1-6 carbon atoms. One methylene (-CH2-) group, of the alkyl, can be replaced by oxygen or sulfur. Alkyl moieties can be optionally substituted by halogen, C3.10 cycloalkyl, amino, C-] _β alkylamino, C-|.g dialkylamino, Cβ-10 ary'. cyano, nitro. Usually alkyl group, in the present case, is methyl.
The term "C3.10 cycloalkyl", as used herein, refers to a monovalent or divalent group of 3 to 10 carbon atoms, derived from a saturated cyclic hydrocarbon. Cycloalkyl groups can be mono- or polycyclic. Cycloalkyl groups can be optionally substituted by halogen or C<|_s alkyl groups as defined above.
The term "C2-6 alkenyl", as used herein, represents a 2-6 carbon atom chain as defined above, having an unsaturated bond.
The term "cyano", as used herein, refers to a group of formula -CN. The term "nitro", as used herein, refers to a group of formula -NO2. The term "amino", as used herein, refers to a group of formula -NH2.
The term "carboxylic acid", as used herein, refers to a group of formula -COOH. The term "halogen", as used herein, refers to an atom of chlorine, bromine, fluorine, iodine. Usually halogen is chlorine.
The term "methoxy", as used herein, refers to a group of formula -OCH3. The term "hydroxyl", as used herein, refers to a group of formula -OH.
The term "Cβ-io ary' " as useα" herein, refers to an organic moiety derived from an aromatic hydrocarbon consisting of a ring or multiple rings, containing 6 to 10 carbon atoms by removal of one hydrogen atom, which can optionally be substituted by amino, C-|_6 alkylamino, C-μβ dialkylamino, C-|_g alkyloxy, C1.5 alkylsulfides, C-\ .Q alkylsulfones, C-] . β alkylsulfoxides, C3.10 cycloalkyl, C-|.β alkyl, halogen.
The term "CQ _-| Q heteroaryl", as used herein refers to a 6 -10 member ring, containing at least one nitrogen atom interrupting the carbocyclic ring structure. The 6 member aromatic heterocycles can be optionally substituted by C-μβ alkyl, C2-6 alkenyl, halogen, C-μβ alkylamino, C-μg dialkylamino, C-|_β alkyloxy, C-j.g alkylsulfides, C-|_β alkylsulfones, C-μg alkylsulfoxides, C3.10 cycloalkyl.
The term "3-10 ring member non-aromatic heterocycle", as used herein refers to a 3 to 10 ring member, containing one N or O heteroatom interrupting the carbocyclic ring structure. The 3-10 ring member non-aromatic heterocycle can be optionally substituted by groups selected from C-) .Q alkyl, halogen, C-|_6 aikylamino, C-|_6 dialkylamino, C3.10 cycloalkyl. The term " C-μβ alkyloxy", as used herein refers, to a refers to a group of formula - ORa, wherein Ra is a C-|_6 alkyl group as defined above.
The term " C-] _Q alkylsulfides", as used herein refers to a group of formula -SRb, wherein R^ is a C-μβ alkyl group as defined above. The term " C-μβ alkylsulfones", as used herein refers to a group of formula -
S(=O)2RC, wherein Rc is a C-|_6 alkyl group as defined above.
The term " C-] .Q alkylsulfoxides", as used herein refers to a group of formula -
Figure imgf000013_0001
is a C-|.β alkyl group as defined above.
The term "C-|-6 alkylamino", as used herein refers to a group of formula -NHRn, wherein Rn is a C<|_6 alkyl group as defined above.
The term "C-|_6 dialkylamino", as used herein refers to a group of formula -NR'RJ, wherein R' is a C-|.β alkyl group as defined above and RJ is a C-|_6 alkyl group as defined above.
Generally X is CH or N. Usually X is CH. Generally W is CH or N. Usually W is N.
Generally R^ is chlorine or methoxy. Usually R^ is chlorine.
Generally R is chlorine or methoxy. Usually R is chlorine.
Generally Y1 is CH, N, CR3, CR10 or CR17. Usually Y1 is CH.
Generally Y2 is CH, N, CR3, CR10 or CR17. Usually Y2 is CH. Generally Y3 is CH, N, CR3, CR10 or CR17. Usually Y3 is CH.
Generally Y4 is CH, N, CR3, CR10 or CR17. Usually Y4 is CH.
Generally Y5 is CH, N, CR3, CR10 or CR17. Usually Y5 is CH.
Generally n is 0 to 3. Usually n is 0.
Generally R2 is C-|_6 alkyl. Usually R2 is methyl. Generally R3 is R4 or -G^ R5.
Generally G1 is -O-, -C(O)-, -S-, -S=O, -S(O)2-, C(O)N(R6)-, -N(R7)C(O)- , - N(RS)S(O)2-, -N(R9)-.
Generally R4 is C-μø alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-) _Q alkylamino, C-μg dialkylamino, Cg-io ary'> cyano, nitro; or is C2-6 alkenyl; or is halogen; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-|_6 alkyl; or is Cg.-io aryl optionally substituted by groups selected from amino, C-|_6 alkylamino, C-|_6 dialkylamino, C-|_β alkyloxy, C-|.β alkylsulfides, C-μβ alkylsulfones, C-|_6 alkylsulfoxides, C3_-| Q cycloalkyl, C-|_6 alkyl, halogen; or is Cg-I o heteroaryl optionally substituted by groups selected from C-|.β alkyl, C2-6 alkenyl, halogen, C-|.β alkylamino, C-μø dialkylamino, C-|.β alkyloxy, C-|.β alkylsulfides, C-|_6 alkylsulfones, C-μø alkylsulfoxides, 03.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_β alkyl, halogen, C-|_6 alkylamino, C-) .5 dialkylamino, C3.10 cycloalkyl; or is hydroxyl; or is carboxylic acid; or is cyano; or is nitro. Generally R^ is hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C<\ _Q alkylamino, C-] _β dialkylamino, Cg-io aryl, cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-) .5 alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-|.g alkylamino, C-μs dialkylamino, C-|_β alkyloxy, C-|.β alkylsulfides, C-μg alkylsulfones, C<\_Q alkylsulfoxides, C3.10 cycloalkyl, C-μρ alkyl, halogen; or is C6-10 heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-|_6 alkylamino, C<|_6 dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-|_6 alkylsulfones, C-i.β alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-μβ alkyl, halogen, C-|_6 alkylamino, C-μβ dialkylamino, C3.10 cycloalkyl.
Generally R^ is hydrogen; or is C<|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-μβ alkylamino, C-|.β dialkylamino, Cβ-10 aryl, cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-μβ alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-|_β alkylamino, C-μø dialkylamino, C-|.β alkyloxy, C<|_6 alkylsulfides, C-|_6 alkylsulfones, C<\_Q alkylsulfoxides, C3.10 cycloalkyl, C-|_6 alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-μg alkylamino, C-|_g dialkylamino, C-|_g alkyloxy, C-|_g alkylsulfides, C-|_g alkylsulfones, C-μg alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-μg alkyl, halogen, C-|_g alkylamino, C-|_g dialkylamino, C3.10 cycloalkyl.
Generally R7 is hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3_<io cycloalkyl, amino, C-| _g alkylamino, C-|_g dialkylamino, Cg. -|rj aryl. cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|_6 alkyl; or is C6-10 aryl optionally substituted by groups selected from amino, C-μg alkylamino, C-μg dialkylamino, C<\ .Q alkyloxy, C-μg alkylsulfides, C-|_g alkylsulfones, C-|_g alkylsulfoxides, C3.-10 cycloalkyl, C-μg alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-μg alkylamino, C-μg dialkylamino, C-μg alkyloxy, C-|_g alkylsulfides, C<\ .Q alkylsulfones, C-μg alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_g alkyl, halogen, C-|_g alkylamino, C-|_g dialkylamino, C3.10 cycloalkyl.
Generally R^ is hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-|.g alkylamino, C-|_6 dialkylamino, Cβ_io ary'. cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|.β alkyl; or is Cg.10 aryl optionally substituted by groups selected from amino, C-|_g alkylamino, C-μg dialkylamino, C-μg alkyloxy, C-|.g alkylsulfides, C-|.g alkylsulfones, C-|.g alkylsulfoxides, C3.10 cycloalkyl, C-|.g alkyl, halogen; or is Cg.10 heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-g alkenyl, halogen, C-μg alkylamino, C-μg dialkylamino, C-|.g alkyloxy, C-|.g alkylsulfides, C<|_g alkylsulfones, C-|.g alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-μg alkyl, halogen, C-|.g alkylamino, C-|.g dialkylamino, C3.10 cycloalkyl.
Generally R^ is hydrogen; or is C-|_g alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-μg alkylamino, C-μg dialkylamino, Cg. -| Q aryi, cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|_g alkyl; or is Cg.10 aιΥ' optionally substituted by groups selected from amino, C-|_g alkylamino, C-|_6 dialkylamino, Ci_g alkyloxy, C-μg alkylsulfides, C-|_6 alkylsulfones, C-|_g alkylsulfoxides, C3.10 cycloalkyl, C1-6 alkyl, halogen; or is Cg-io heteroaryl optionally substituted by groups selected from C<|_g alkyl, C2_6 alkenyl, halogen, C-μg alkylamino, C1.5 dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-|_g alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_g alkyl, halogen, C-|_6 alkylamino, C-|_g dialkylamino, C3.10 cycloalkyl.
Generally R10 is R1 1 or -G2R12-
Generally G2 is -O-, -C(O)-, -S-, -S=O, -S(O)2-, C(O)N(R"! 3)-, -N(R1^)C(O)- , - N(R1 S)S(O)2-, -N(R16)-.
Generally m is O to 3. Usually m is O. Generally R1 1 is C-μg alkyl optionally substituted by groups selected from halogen,
C3.10 cycloalkyl, amino, C-1.5 alkylamino, C-|_g dialkylamino, Cg.10 a|7l. cyano, nitro; or is C2_6 alkenyl; or is halogen; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|_g alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-|_g alkylamino, C-μg dialkylamino, C-|_g alkyloxy, C-μg alkylsulfides, C<\_Q alkylsulfones, C1.5 alkylsulfoxides, C3.10 cycloalkyl, C-|_g alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μg alkyl, C2_6 alkenyl, halogen, C-μg alkylamino, C-j.g dialkylamino, C-|_g alkyloxy, C^.β alkylsulfides, C-|_6 alkylsulfones, C-j.g alkylsulfoxides, C3.-10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-μg alkyl, halogen, C-|_6 alkylamino, C-) .Q dialkylamino, C3.10 cycloalkyl; or is hydroxyl; or is carboxylic acid; or is cyano; or is nitro.
Generally R12 is hydrogen; or is C-|_5 alkyi optionally substituted by groups selected from halogen, C3_-|n cycloalkyl, amino, Ci_6 alkylamino, C-μg dialkylamino, CQ.*\ Q aryl, cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|_g alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-| _g alkylamino, C-|_g dialkylamino, C-|_g alkyloxy, C-|_6 alkylsulfides, C-|_6 alkylsulfones, C-|_g alkylsulfoxides, C3.10 cycloalkyl, C-|_β alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-μg alkylamino, C-μg dialkylamino, C-|_g alkyloxy, C-μg alkylsulfides, C-|_g alkylsulfones, C-|_g alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_6 alkyl, halogen, C-|_6 alkylamino, C-|_6 dialkylamino, C^.10 cycloalkyl.
Generally R^ js hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-|_g alkylamino, C-|_6 dialkylamino, Cg.10 ary'- cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-μg alkyl; or is Cβ-io ary' optionally substituted by groups selected from amino, C-μg alkylamino, C-μg dialkylamino, C-j.g alkyloxy, C1.5 alkylsulfides, C-|_g alkylsulfones, C-|_g alkylsulfoxides, C3.10 cycloalkyl, C-] .5 alkyl, halogen; or is Cρ-10 heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-μø alkylamino, C-|_6 dialkylamino, C-|_6 alkyloxy, C-|_β alkylsulfides, C-|_6 alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_6 alkyl, halogen, C<|_6 alkylamino, C<|_6 dialkylamino, C3.-10 cycloalkyl.
Generally R^4 is hydrogen; or is C-|_5 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-|.β alkylamino, C-|_s dialkylamino, Cg.10 aryl, cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-μρ alkyl; or is Cg-io afy! optionally substituted by groups selected from amino, C^ _g alkylamino, C-|.g dialkylamino, C-|.g alkyloxy, C-|.g alkylsulfides, C-|_g alkylsulfones, C-|.g alkylsulfoxides, C3.-10 cycloalkyl, C-] _g alkyl, halogen; or is Cg.10 heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-g alkenyl, halogen, C-μg alkylamino, C-|_g dialkylamino, C-|_g alkyloxy, C-|.g alkylsulfides, C-\ _g alkylsulfones, C-|.g alkylsulfoxides, C3.10 cycloalkyi; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-μø alkyl, halogen, C-|.β alkylamino, C-μβ dialkylamino, C3.10 cycloalkyl.
Generally R15 js hydrogen; or is C-j. β alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C-|_6 alkylamino, C-|.β dialkylamino, Cβ-io aryl, cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|_6 alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-|_ 6 alkylamino, C-|_β dialkylamino, C-|_6 alkyloxy, C-|.β alkylsulfides, C-j_g alkylsulfones, C-|.β alkylsulfoxides, C3.10 cycloalkyl, C^.g alkyl, halogen; or is Cg-10 heteroaryl optionally substituted by groups selected from C-|_6 alkyl, C2-6 alkenyl, halogen, C-|.g alkylamino, C-|_6 dialkylamino, C-j_6 alkyloxy, C-|_6 alkylsulfides, C-|_6 alkylsulfones, C-|_β alkylsulfoxides, C3.-10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_6 alkyl, halogen, C-|_6 alkylamino, C-j.β dialkylamino, C3.-10 cycloalkyl.
Generally R^ js hydrogen; or is C-j.6 alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C-j.β alkylamino, C-|_6 dialkylamino, Cβ-10 aryl, cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-|_6 alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-j_6 alkylamino, C-μg dialkylamino, C-|_β alkyloxy, C-|_β alkylsulfides, C-|_6 alkylsulfones, C-μg alkylsulfoxides, C3.10 cycloalkyl, C-|_β alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-|_s alkyl, C2-6 alkenyl, halogen, C-|_6 alkylamino, C-|_6 dialkylamino, C-|_6 alkyloxy, C-j_6 alkylsulfides, C-|_6 alkylsulfones, C-|_6 alkylsulfoxides, C3.-10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_β alkyl, halogen, C-j.β alkylamino, C-|_6 dialkylamino, C3.10 cycloalkyl.
Generally R1 7 is R18 or -G3R19. Generally G3 is -O-, -C(O)-, -S-, -S=O, -S(O)2-, C(O)N(R20)-, -N(R21)C(O)- , -
N(R22JS(O)2-, -N(R23)-.
Generally o is O to 3. Usually o is O.
Generally R18 is C-|.β alkyl optionally substituted by groups selected from halogen, C3_io cycioalkyl, amino, C-|.β alkylamino, C-|_β dialkylamino, Cs-io aryl, cyano, nitro; or is C2_5 alkenyl; or is halogen; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-| _Q alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-|.g alkylamino, C-μs dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C<|_6 alkylsulfones, C-|_s alkylsulfoxides, C3.10 cycloalkyl, C-μβ alkyl, halogen; or is Cβ_io heteroaryl optionally substituted by groups selected from C-|_6 alkyl, C2-6 alkenyl, halogen, C-) .5 alkylamino, C-μβ dialkylamino, C-|_β alkyloxy, C-μβ alkylsulfides, C-|_6 alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|.g alkyl, halogen, C-μg alkylamino, C-|_β dialkylamino, C3.10 cycloalkyl; or is hydroxyl; or is carboxylic acid; or is cyano; or is nitro.
Generally R^ is hydrogen; or is C-) .5 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-\ .Q alkylamino, C-μg dialkylamino, Cg.10 aryl> cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|_6 alkyl; or is CQ-10 aryl optionally substituted by groups selected from amino, C-μs alkylamino, C-] _g dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-|_6 alkylsulfones, C-1.5 alkylsulfoxides, C3.10 cycloalkyl, C-j.β alkyl, halogen; or is C6-10 heteroaryl optionally substituted by groups selected from C-μβ alkyl, C2-6 alkenyl, halogen, C-|_6 alkylamino, C-|.β dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-|.g alkylsulfones, C-μβ alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|.β alkyl, halogen, C-|_6 alkylamino, C-|_6 dialkylamino, C3.10 cycloalkyl.
Generally R^O js hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-μβ alkylamino, C-] _β dialkylamino, Cβ-io ary'- cyano, nitro; or is C3_io cycloalkyl optionally substituted by groups selected from halogen, C-j.β alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-] .Q alkylamino, C-μg dialkylamino, C-|_s alkyloxy, C-|_β alkylsulfides, C-μβ alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl, C-μs alkyl, halogen; or is Cβ-i o heteroaryl optionally substituted by groups selected from C-μβ alkyl, C2-6 alkenyl, halogen, C-μg alkylamino, C-μg dialkylamino, C-|.β alkyloxy, C-μø alkylsulfides, C-|_6 alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C<|_6 alkyl, halogen, C-|_6 alkylamino, C-|_6 dialkylamino, C3.10 cycloalkyl.
Generally R21 is hydrogen; or is Ci_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-μβ alkylamino, C-|_ρ dialkylamino, C5.10 aryl. cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-μβ alkyl; or is Cβ-io ary! optionally substituted by groups selected from amino, C-μβ alkylamino, C-μβ dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-j.6 alkylsulfones, C<|_6 alkylsulfoxides, C3.-10 cycloalkyl, C-|.g alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C^ _Q alkyl, C2-6 alkenyl, halogen, C-|_β alkylamino, C-|.g dialkylamino, C-|.β alkyloxy, Ci_β alkylsulfides, C-|.g alkylsulfones, C-|.β alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_6 alkyl, halogen, C-|_6 alkylamino, C-|_β dialkylamino, C3.-10 cycloalkyl.
Generally R^2 js hydrogen; or is C-| .6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-j.β alkylamino, C-|_s dialkylamino, Cg-10 ary'> cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|_6 alkyl; or is Cβ-10 aryl optionally substituted by groups selected from amino, C-|.β alkylamino, C-μβ dialkylamino, C-|.g alkyloxy, C-|_6 alkylsulfides, C-μg alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl, C-|.β alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μβ alkyl,
C2-6 alkenyl, halogen, C-μβ alkylamino, C-|_6 dialkylamino, C-μβ alkyloxy, C-|.β alkylsulfides, C-|.β alkylsulfones, C<|_6 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-μg alkyl, halogen, Ci_6 alkylamino, C-|_s dialkylamino, C3.10 cycloalkyl. Generally R^3 is hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C-μg alkylamino, C-μø dialkylamino, CQ.-\ Q aryl, cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-μg alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-|_6 alkylamino, C<\ _Q dialkylamino, C-|_6 alkyloxy, C-|_β alkylsulfides, C-μs alkylsulfones, C-|_6 alkylsulfoxides, C3.-10 cycloalkyl, Ci_ρ alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μβ alkyl, C2-6 alkenyl, halogen, C-|.g alkylamino, C-\.Q dialkylamino, C^.g alkyloxy, C-μø alkylsulfides, C-μg alkylsulfones, C-μø alkylsulfoxides, C3.-10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_g alkyl, halogen, C-|_β alkylamino, C-|.ρ dialkylamino, C3.10 cycloalkyl.
In a preferred embodiment of the invention X is CH; and W is N; and R^ is chlorine; and R is chlorine; and R2 is C<\ _Q alkyl; and n is 0; and m is 0; and o is 0; and Y1 is CH; and Y2 is CH; and Y3 is CH; and Y4 is CH and Y5 is CH.
Compounds of formula I and some of their intermediates have at least one stereogenic centre in their structure. This stereogenic centre may be present in "R" or "S" configuration, said "R" and "S" notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-30. In all the above-mentioned scopes, the asymmetric carbon atom, is preferably in the "S" configuration.
The "pharmaceutically acceptable salts" according to the invention include therapeutically active, non-toxic base and acid salt forms which the compounds of formula I are able to form. The acid addition salt form of a compound of formula I that occurs in its free form as a base can be obtained by treating the free base with an appropriate acid such as an inorganic acid, for example, a hydrohalic such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and the like; or an organic acid, such as, for example, acetic, hydroxyacetic, propanoic, lactic, pyruvic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p- aminosalicylic, pamoic, formic and the like (Handbook of Pharmaceutical Salts, P. Heinrich Stahl & Camille G. Wermuth (Eds), Verlag Helvetica Chimica Acta - Zurich, 2002, 329- 345).
The compounds of formula I containing acidic protons may be converted into their therapeutically active, non-toxic base addition salt forms, e.g. metal or amine salts, by treatment with appropriate organic and inorganic bases. Appropriate base salt forms include, for example, ammonium salts, alkali and earth alkaline metal salts, e.g. lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. N-methyl-D-glucamine salts, and salts with amino acids such as, for example, arginine, lysine and the like (Handbook of Pharmaceutical Salts, P. Heinrich Stahl & Camille G. Wermuth (Eds), Verlag Helvetica Chimica Acta - Zurich, 2002, 329-345). Conversely said salt forms can be converted into the free forms by treatment with an appropriate base or acid.
Compounds of formula I and their salts can be in the form of a solvate. Such solvates include for example hydrates, alcoholates and the like.
The invention also relates to all stereoisomeric forms such as enantiomeric and diastereoisomeric forms of the compounds of formula I or mixtures thereof (including all possible mixtures of stereoisomers).
Some of the compounds of formula I may also exist in tautomeric forms. With respect to the present invention reference to a compound or compounds, is intended to encompass that compound in each of its possible isomeric forms and mixtures thereof unless the particular isomeric form is referred to specifically.
Compounds according to the present invention may exist in different polymorphic forms. The present invention concerns also processes for preparing the compounds of formula I.
When compounds of formula I present one stereogenic centre, and that non- stereoselective methods of synthesis are used, resolution of the mixture of stereoisomers can best be effected in one or several steps, involving generally sequential separation of mixtures of diastereomers into their constituting racemates, using preferably chromatographic separations on achiral or chiral phase in reversed or preferably in direct mode, followed by at least one ultimate step of resolution of each racemate into its enantiomers, using most preferably chromatographic separation on chiral phase in reversed or preferably in direct mode. Alternatively, when partly stereoselective methods of synthesis are used, the ultimate step may be a separation of diastereomers using preferably chromatographic separations on achiral or chiral phase in reversed or preferably in direct mode.
It has now been found that compounds of formula I and their pharmaceutically acceptable salts are useful in a variety of pharmaceutical indications. For example, the compounds according to the invention are useful for the treatment of asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, α4-related cancers such as lung e.g. non-small cell lung, pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer. Thus, the present invention, in a further aspect, concerns the use of a compound of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of disorders such as mentioned above.
In particular, the present invention concerns the use of a compound of formula I or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of α4 dependent inflammatory or medical conditions such as for example asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, oc4-related cancers such as lung e.g. non-small cell lung, pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer.
The compounds of the invention are useful for treating conditions mediated by adhesion mechanisms. These conditions include asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, α4-related cancers such as lung e.g. non-small cell lung, pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer.
Subjects in need of treatment for a α4 dependent inflammatory or medical condition, asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, α4-related cancers such as lung e.g. non-small cell lung, pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer, can be treated by administering to the patient an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable derivative or salt thereof in a pharmaceutically acceptable carrier or diluent to reduce formation of oxygen radicals. The active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermal^, subcutaneously, intramuscularly or topically, in liquid, cream, gel or solid form, via a buccal or nasal spray, or aerosol, a patch or suppositories. The invention further concerns the use of the compounds of formula I for the manufacture of a medicament for therapeutic application. In particular, the invention concerns the use of the compounds of formula I for the manufacture of a medicament useful for treating conditions in which there is likely to be a α4 dependent component. The invention concerns the use of the compound of formula I for the manufacture of a medicament useful for treating asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, α4-related cancers such as lung e.g. non-small cell lung, pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer.
The invention further concerns the compounds of formula I for use as medicaments. The invention concerns the compounds of formula I for use as a medicament for treating asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, α4-related cancers such as lung e.g. non-small cell lung, pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer. The activity and properties of the active compounds, oral availability and stability in vitro or in vivo can vary significantly among the optical isomers of the disclosed compounds.
In a preferred embodiment, the active compound is administered in an enantiomerically enriched form, i.e., substantially in the form of one isomer.
The present invention also concerns a method for treating α4 dependent inflammatory or medical condition (preferably asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, α4-related cancers such as lung e.g. non-small cell lung, pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer) in a mammal in need of such treatment, comprising administering a therapeutic dose of at least one compound of formula I or a pharmaceutically acceptable salt thereof to a patient.
The methods of the invention comprise administration to a mammal (preferably human) suffering from above mentioned conditions or disorders, of a compound according to the invention in an amount sufficient to alleviate or prevent the disorder or condition. The compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing 0.01 to 2000 mg, preferably 0.05 to 500 mg of active ingredient per unit dosage form.
The term "treatment" as used herein includes curative treatment and prophylactic treatment. The term "substantially" as used herein refers to a composition of equal or higher than 85% of one isomer, usually 90 % and preferably 95%.
By "curative" is meant efficacy in treating a current symptomatic episode of a disorder or condition.
By "prophylactic" is meant prevention of the occurrence or recurrence of a disorder or condition.
The compounds are of use in modulating cell adhesion and in particular are of use in the prophylaxis and treatment of diseases or disorders in which the extravasation of leukocytes plays a role and the invention extends to such a use and to the use of the compounds for the manufacture of a medicament for treating such diseases or disorders. Diseases or disorders of this type include inflammatory arthritis such as rheumatoid arthritis, vasculitis or polydermatomyositis, multiple sclerosis, transplantation, diabetes, inflammatory dermatoses such as psoriasis or dermatitis, asthma and inflammatory bowel disease. One aspect of the invention includes methods for treating α4-related cancers
(including cancers, whether solid or haematopoietic). Examples of such cancers include, but are not limited to, lung e.g. non-small cell lung, pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer. Results obtained with compounds of formula I are indicative of a strong pharmacological effect.
For treating diseases, compounds of formula I or their pharmaceutically acceptable salts, may be employed at an effective daily dosage and administered in the form of a pharmaceutical composition. Therefore, another embodiment of the present invention concerns a pharmaceutical composition comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable diluent or carrier.
To prepare a pharmaceutical composition according to the invention, one or more of the compounds of formula I or a pharmaceutically acceptable salt thereof, is intimately admixed with a pharmaceutical diluent or carrier according to conventional pharmaceutical compounding techniques known to the skilled practitioner.
Suitable diluents and carriers may take a wide variety of forms depending on the desired route of administration, e.g., oral, rectal, or parenteral. Pharmaceutical compositions comprising compounds according to the invention can, for example, be administered orally or parenterally, i.e., intravenously, intramuscularly, subcutaneously or intrathecally.
Pharmaceutical compositions suitable for oral administration can be solids or liquids and can, for example, be in the form of tablets, pills, dragees, gelatine capsules, solutions, syrups, and the like.
To this end the active ingredient may be mixed with an inert diluent or a non-toxic pharmaceutically acceptable carrier such as starch or lactose. Optionally, these pharmaceutical compositions can also contain a binder such as microcrystalline cellulose, gum tragacanth or gelatine, a disintegrant such as alginic acid, a lubricant such as magnesium stearate, a glidant such as colloidal silicon dioxide, a sweetener such as sucrose or saccharin, or colouring agents or a flavouring agent such as peppermint or methyl salicylate.
The invention also contemplates compositions which can release the active substance in a controlled manner. Pharmaceutical compositions which can be used for parenteral administration are in conventional form such as aqueous or oily solutions or suspensions generally contained in ampoules, disposable syringes, glass or plastics vials or infusion containers.
In addition to the active ingredient, these solutions or suspensions can optionally also contain a sterile diluent such as water for injection, a physiological saline solution, oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents, antibacterial agents such as benzyl alcohol, antioxidants such as ascorbic acid or sodium bisulphite, chelating agents such as ethylene diamine-tetra-acetic acid, buffers such as acetates, citrates or phosphates and agents for adjusting the osmolarity, such as sodium chloride or dextrose. These pharmaceutical forms are prepared using methods which are routinely used by pharmacists.
The amount of active ingredient in the pharmaceutical compositions can fall within a wide range of concentrations and depends on a variety of factors such as the patient's sex, age, weight and medical condition, as well as on the method of administration. Thus the quantity of compound of formula I in compositions for oral administration is at least 0.5 % by weight and can be up to 80 % by weight with respect to the total weight of the composition.
For the preferred oral compositions, the daily dosage is in the range 0.01 to 2000 milligrams (mg) of compounds of formula I. In compositions for parenteral administration, the quantity of compound of formula I present is at least 0.5 % by weight and can be up to 33 % by weight with respect to the total weight of the composition. For the preferred parenteral compositions, the dosage unit is in the range 0.01 mg to 2000 mg of compounds of formula I.
The daily dose can fall within a wide range of dosage units of compound of formula I and is generally in the range 0.01 to 2000 mg. However, it should be understood that the specific doses could be adapted to particular cases depending on the individual requirements, at the physician's discretion.
The compounds of the invention may be co-administered with another therapeutic agent most likely from a different therapeutic area. Co-administration in this context means the dosing either of components, which are formulated together as a single dosage form; or the administration of separately formulated agents at substantially the same time, or sequential dosing of a compound of the invention followed by a therapeutic agent of a different therapeutic area. In this context suitable examples of therapeutic agents may include, but are not limited to, histamine H1 antagonists such as cetirizine, histamine H2 antagonists, histamine H3 antagonists, leukotriene antagonists, PDE4 inhibitors such as 3-cyclo- propylmethoxy-4-difluoromethoxy-Λ/-[3,5-di-chloropyrid-4-yl]-benzamide, muscarinic M3 antagonists, β2 agonists, theophylline, sodium cromoglycate, anti-TNF antibodies such as certolizumab pegol or adalimumab, anti-IL6 antibodies, anti-IL17 antibodies, adhesion molecule inhibitors, inhibitors of cytokine synthesis such as P38 MAP kinase inhibitors and inhibitors of PI3 kinase, methotrexate.
The present invention concerns also processes for preparing the compounds of formula I. The compounds of formula I according to the invention can be prepared analogously to conventional methods as understood by the person skilled in the art of synthetic organic chemistry.
The following processes description sets forth certain synthesis routes in an illustrative manner. Other alternative and/or analogous methods will be readily apparent to those skilled in this art.
Most compounds of formula I may be prepared according to the following scheme:
Scheme 1
Figure imgf000029_0001
CDI
Figure imgf000029_0002
Most compounds of formula I may be prepared according to scheme 1 , starting with the 6-quinolinepropanoic acid 1-(2,6-dichlorophenyl)-α-[[(1 ,1- dimethylethoxy)carbonyl]amino]-, methylester (RN-623144-13-8). The /"-butyl group is removed using Trifluoroacetic acid in dichloromethane to yield the free amine. The amino group is coupled with an aniline or heteroaromatic 6 member ring amine in the presence of carboyldiimidazole (CDI). Saponification of the ester to the acid using 2N sodium hydroxide (NaOH) yields the desired product.
Compounds of formula Ia can be prepared according to scheme 1 , starting with Methyl-(2S)-2-[(tert-butoxycarbonyl)amino]-3-[2-(2,6-dichlorophenyl)-6- quinolinyl]propanoate (RN 623144-30-9).
The present invention also relates to synthetic intermediates geometrical isomers, enantiomers, diastereoisomers, pharmaceutically acceptable salts and all possible mixtures thereof.
The following examples are provided for illustrative purposes only and are not intended, nor should they be construed, as limiting the invention in any manner.
Unless specified otherwise in the examples, characterization of the compounds is performed according to (LCMS) liquid chromatography mass spectra, preparative liquid chromatography LC, NMR, and silica gel chromatography methods. NMR spectra are recorded on Bruker AV300 and DRX 400 spectrometers at 300 and 400 MHz respectively. Chromatographic separations are performed on Davis 5 μM silica gel.
The Waters mass spectrometers used are of model ZMD or ZQ both Waters.
Various reactions took place in an Emrys Optimiser microwave reactor.
The following abbreviations are used in the examples: CD3OD- d4-MeOH - Methanol^; NaOH - sodium hydroxide
TBS - Tris buffered saline RT - Retention time;
TEA - Triethylamine;
MeCN - acetonitrile EtOAc - ethyl acetate
NaHCθ3 - sodium hydrogen carbonate DCM - dichloromethane THF - tetrahydrofuran MgSθ4 - magnesium sulfate
MnCl2 - manganese chloride PBS Phosphate buffer system
LCMS Prep LC conditions and abbreviations
The following LCMS conditions are used to obtain the retention times (RT) as described herein: LCMS conditions (Method A):
HP1100 (Diode Array) linked to a Finnigan LC-Q Mass Spectrometer, ESI mode with Pos/Neg ionisation
Column: Luna C18(2) 100χ4.6mm, 5μm particle size Analytical column
Column Temp: 350C Mobile Phase:A: Water + 0.08% formic acid
B: Acetonitrile + 0.08% formic acid Flow rate: 3ml/min Gradient: Time (mins): % Composition B:
0 5 4.4 95
5.30 95
5.32 5
6.5 5
Run time: 6.5 mins Typical Injection VoI: 10μl
Detector Wavelength: DAD 200-400nm Preparative LC conditions (Method B): Gilson 215 liquid handler setup.
Column: Luna C18(2) 250x21.2mm, 5μM particle size prep column Column Temp: Ambient Gradient: Variable - depends on retention time of sample in LC-MS analysis.
Run Time: 20 mins
Flow rate: 25ml/min
Typical Injection VoI: 0.5 - 4.0ml at 25mg/ml Detector Wavelength:210 and 254nm
Mobile Phase: A: Water + 0.08% formic acid
B: Acetonitrile + 0.08% formic acid The IUPAC names of the compounds mentioned in the examples are generated with ACD version 6.00. Unless specified otherwise in the examples, characterization of the compounds is performed according to the following methods:
NMR spectra are recorded on a Bruker AV-300 or DRX-400 Spectrometers operating at 300.13 MHz or 400.13 MHz for protons, and running the Bruker XWINNMR software package. Spectra are acquired at room temperature unless otherwise stated. Chemical shifts are given in ppm referenced either to internal TMS or to the residual solvent signal.
Synthetic example:
Example 1 : Synthesis of (2S)-3-r2-(216-dichlorophenyl)quinolin-6-vn-2-
(rmethyl(phenyl)carbamovnamino)propanoic acid (Compound 1) Ethyl-(2S)-2-[(tert-butoxycarbonyl)amino]-3-[2-(2,6-dichlorophenyl)-6- quinolinyl]propanoate (prepared in the same manner as RN 623144-30-9, starting from
(S)-4-Nitrophenylalanine ethyl ester RN 34276-53-4) (2.46g) is dissolved in dichloromethane (25ml) and a solution of trifluoroacetic acid (4.6ml) in dichloromethane
(5ml) is added drop wise over 10 minutes. After addition is complete the reaction is stirred at RT over night, before being diluted with EtOAc and washed with a saturated NaHCC>3 solution and the solvent is removed in vacuo. The resultant oil is taken up in DCMTHF
(5:1 , 40ml) and carboyldiimidazole is added (820mg) and the reaction is stirred at room temperature for 1hour. The reaction is washed with water (25ml) and dried over MgSO4, before the solvent is removed in vacuo to yield yellow oil, of which 50mgs are taken up in MeCN (2ml) and N-methyl aniline (0.011ml) is added. The reation is heated for IOmins in a microwave reactor, before the reation is added dropwise to a 2N NaOH solution (2ml) and stirred over night at room temperature. The reaction is evaporated to dryness and purified by mass triggered prep HPLC (Method B) to yield the title compound (16mg) as a white solid. LCMS (Method A) M+1 (494, 496), RT 3.51 min, 1 H NMR, 300Mz, CD3OD § 3.19 (s, 3H), 3.25 (dd, 1H), 3.41 (1 H, dd), 4.69 (dt, 1 H), 5.35 (d, 1H), 7.08 (dd, 2H), 7.18-7.29 (3H, m), 7.49-7.64 (m, 5H), 7.70 (1 H, d), 7.96 (1H, d), 8.14 (1 H, s), 8.40 (1 H). Biological example: Example 2 The following protein assay is used to demonstrate the potency of the compounds according to the invention. In this assay an IC50 value is determined for each test compound and represents the concentration of compound necessary to achieve 50% inhibition of binding VCAM-mFc / a4b1-hFc protein binding assay in DELFIA format.
100μl/well of a 5μg/ml solution of F(ab')2 fragment goat anti-mouse Fc antibody (Stratech) in PBS was added to a 96 well microtiter plate (Nunc Maxisorp) and incubated overnight at 40C. Unbound antibody was removed and plates were washed 3x 200μl with PBS. 200μl of blocking buffer (PBS, 2% BSA, 1% TWEEN20) was added to all wells and incubated at room temperature for 1 hour. Blocking buffer was removed and plates were washed with 3 x 200μl PBS. 40μl of a 375ng/ml solution of recombinant VCAM-mFc prepared in conjugate buffer (2OmM Tris, 15OmM NaCI, 1mM MnCI2, 1% Ovalbumin, 0.1% TWEEN20 pH7.5) was added to each well. 10μl of test compound prepared at various concentrations in conjugate buffer containing 5% DMSO was added to the plate. Finally, 50μl of a 400ng/ml solution of recombinant a4b1-hFc prepared in conjugate buffer containing 2μg/ml F(ab')2 fragment goat anti-human Fc antibody labelled with Europium (antibody- Stratech, Europium label -Perkin Elemer) was added to the plate. The binding reaction was incubated at room temperature for 2 hours whilst shaking gently.
The well contents was removed and plates were washed 3 x 200μl with wash buffer (2OmM Tris, 15OmM NaCI1ImM MnCI2). 100μl of DELFIA enhancement solution (Perkin Elmer) was added to all wells and plates incubated for 30 minutes at room temperature.
Time-resolved fluorescence was measured on a TECAN Ultra plate reader (Ex320nM, Em
612nM) and test compound IC50 values calculated.
The compounds of the invention are tested in this assay and show IC50 values of
5OnM and below. (2S)-3-[2-(2,6-dichlorophenyl)quinolin-6-yl]-2-{[methyl(phenyl)carbamoyl]amino}propanoic acid has an activity between 30 and 50 nM in the above assay.

Claims

1. A compound having formula I or pharmaceutically acceptable salts thereof or stereoisomeric forms thereof, and the geometrical isomers, enantiomers, diastereoisomers, and pharmaceutically acceptable salts thereof
Figure imgf000033_0001
formula I wherein: X is CH or N;
W is CH or N;
R is chlorine or methoxy;
R1 is chlorine or methoxy;
Y1 is CH, N, CR3, CR10 or CR17; Y2 is CH, N, CR3, CR10 or CR17;
Y3 is CH, N, CR3, CR10 or CR17;
Y4 is CH, N, CR3, CR10 or CR17; γ5 is CH, N, CR3, CR10 or CR17; n = 0 to 3; R2 is C-|_6 alkyl;
R3 Js R4 Or -G1 R5;
G1 is -O-, -C(O)-, -S-, -S=O, -S(O)2-, C(O)N(R6)-, -N(R7)C(O)- , -N(R8)S(O)2-
N(R9)-;
R4 is C-|_5 alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C-μβ alkylamino, C-j.β dialkylamino, Cg^o ary'. cyano, nitro; or is C2-6 alkenyl; or is halogen; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C^ _g alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-μg alkylamino, C-|_g dialkylamino, C-|_g alkyloxy, C-|_g alkylsulfides, C-μg alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl, C-μg alkyl, halogen; or is Cg-io heteroaryl optionally substituted by groups selected from C-|_6 alkyl, C2-6 alkenyl, halogen, C-|_g alkylamino, C-|_6 dialkylamino, C-|_6 alkyloxy, C-μg alkylsulfides, C-i_6 alkylsulfones, C-|_g alkylsulfoxides, C3_-| Q cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-μg alkyl, halogen, C-|_g alkylamino, C-μg dialkylamino, C3.10 cycloalkyl; or is hydroxyl; or is carboxylic acid; or is cyano; or is nitro;
R5 is hydrogen; or is C<|_6 alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C1-6 alkylamino, C1-6 dialkylamino, Cg. -| Q aryl, cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|_g alkyl; or is Cg.10 aryl optionally substituted by groups selected from amino, C-] _g alkylamino, C-|.g dialkylamino, C-|.g alkyloxy, C-|.g alkylsulfides, C-|.g alkylsulfones, C-|.g alkylsulfoxides, C3.10 cycloalkyl, C1-6 alkyl, halogen; or is Cg_-|o heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-g alkenyl, halogen, C-|.g alkylamino, C-μg dialkylamino, C-|_g alkyloxy, C-μg alkylsulfides, C-μg alkylsulfones, C-|_g alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|.g alkyl, halogen, C-|_g alkylamino, C<|_g dialkylamino, C3.10 cycloalkyl;
R6 is hydrogen; or is C-|.g alkyl optionally substituted by groups selected from halogen, C3_I Q cycloalkyl, amino, C-μg alkylamino, C-] _g dialkylamino, Cg.10 aryl, cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|_ g alkyl; or is Cg-io ary' optionally substituted by groups selected from amino, C-|_g alkylamino, C-μg dialkylamino, C-|_g alkyloxy, C-|_s alkylsulfides, C-|_g alkylsulfones, C-|_g alkylsulfoxides, C3_-| Q cycloalkyl, C-|_g alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-μg alkylamino, C-μg dialkylamino, C<\_Q alkyloxy, C-|_g alkylsulfides, C-|_6 alkylsulfones, C-|_g alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_6 alkyl, halogen, C-|_6 alkylamino, C-μg dialkylamino, C3.10 cycloalkyl;
R? is hydrogen; or is C-] _6 alkyl optionally substituted by groups selected from halogen, 03.10 cycloalkyl, amino, C-|_g alkylamino, C-μg dialkylamino, Cg.10 ary'- cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|_g alkyl; or is Cg-io ary! optionally substituted by groups selected from amino, C-|_g alkylamino, C-μg dialkylamino, C-|_g alkyloxy, C-|_g alkylsulfides, C-μg alkylsulfones, C-|.β alkylsulfoxides, C3_-| Q cycloalkyl, C-|_g alkyl, halogen; or is Cg.10 heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-g alkenyl, halogen, C-|.g alkylamino, C-|_g dialkylamino, C-|.g alkyloxy, C-|.g alkylsulfides, C-μg alkylsulfones, C-|.g alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C<|_g alkyl, halogen, C-|.g alkylamino, C-|.g dialkylamino, 03. -| Q cycloalkyl;
R8 is hydrogen; or is C<|_g alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-μg alkylamino, C-|_g dialkylamino, Cg.10 aryl, cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-|.g alkyl; or is Cg.10 aryl optionally substituted by groups selected from amino, C-μg alkylamino, C-| _g dialkylamino, C-μg alkyloxy, C-|.g alkylsulfides, Ci_g alkylsulfones, C-|.g alkylsulfoxides, C3.10 cycloalkyl, C-|.g alkyl, halogen; or is Cg.10 heteroaryl optionally substituted by groups selected from C-μg alkyl,
C2-g alkenyl, halogen, C-|_g alkylamino, C-|.g dialkylamino, C-|.g alkyloxy, C-|_g alkylsulfides, C-|.g alkylsulfones, C-|.g alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_g alkyl, halogen, C-|_g alkylamino, C-|.g diaikylamino, C3.10 cycloalkyl; R9 is hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, Ci_β alkylamino, C-|.β dialkylamino, C5.10 aryl, cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-μβ alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-|_6 alkylamino, C-μe dialkylamino, C<|_6 alkyloxy, C-|_6 alkylsulfides, C^\.Q alkylsulfones, Ci_6 alkylsulfoxides, C3.10 cycloalkyl, C-|.β alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μø alkyl, C2-6 alkenyl, halogen, C-|_6 alkylamino, C-μβ dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-] .Q alkylsulfones, C-] _Q alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|.g alkyl, halogen, C^.g alkylamino, C-μβ dialkylamino, C3.10 cycloalkyl;
R1O iS R1 1 OΓ -G2 R1 2;
G2 is -O-, -C(O)-, -S-, -S=O, -S(O)2-, C(O)N(R13)-, -N(R14)C(O)- , -N(R1S)S(O)2-, - N(R16)-; m is O to 3;
R1 1 is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-|.β alkylamino, C-|.g dialkylamino, Cβ_io arY'> cyano, nitro; or is C2_6 alkenyl; or is halogen; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-μρ alkyl; or is Cg-i o aryl optionally substituted by groups selected from amino, C-|.g alkylamino, C-μg dialkylamino, C-|.β alkyloxy, C-μg alkylsulfides, C-μβ alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl, C-|_6 alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μβ alkyl, C2_5 alkenyl, halogen, C-|_β alkylamino, C-i.β dialkylamino, C-μø alkyloxy, C^.β alkylsulfides, C-|_6 alkylsulfones, C-μβ alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-μø alkyl, halogen, C-|_6 alkylamino, C-μβ dialkylamino, C3.10 cycloalkyl; or is hydroxyl; or is carboxylic acid; or is cyano; or is nitro; R12 is hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C<|_6 alkylamino, C-|.β dialkylamino, Cβ-io aryl, cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-|_6 alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C^ _β alkylamino, C-μβ dialkylamino, C-|_6 alkyloxy, C-μβ alkylsulfides, C-|_6 alkylsulfones, C-|.β alkylsulfoxides, C3.10 cycloalkyl, C-|.β alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C<|_6 alkyl, C2-6 alkenyl, halogen, C-μβ alkylamino, C-|.β dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-|_β alkylsulfones, C-|_5 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_β alkyl, halogen, C-j.g alkylamino, C-|_6 dialkylamino, C3.10 cycloalkyl;
R13 is hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.-10 cycloalkyl, amino, C-μg alkylamino, C^.Q dialkylamino, Cg-io aryl. cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-|_6 alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-|.β alkylamino, C-μβ dialkylamino, C-|.ρ alkyloxy, C-|.g alkylsulfides, C-μg alkylsulfones, C-\.Q alkylsulfoxides, C3.10 cycloalkyl, C-1.5 alkyl, halogen; or is Cβ-10 heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-|_6 alkylamino, C-μρ dialkylamino, C-|_6 alkyloxy, C-|_6 alkylsulfides, C-μs alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|.β alkyl, halogen, C<|_6 alkylamino, C<\ .Q dialkylamino, C3.10 cycloalkyl;
R^4 is hydrogen; or is C<|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-μg alkylamino, C-μβ dialkylamino, C6_<|rj aryl, cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-μg alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-|_6 alkylamino, C-μø dialkylamino, C-|.ρ alkyloxy, C-|_6 alkylsulfides, C-|_6 alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl, C-j.β alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-] _β alkyl, C2-6 alkenyl, halogen, C-\ .Q alkylamino, C-|.g dialkylamino, C<|_6 alkyloxy, C-|_6 alkylsulfides, C-|_6 alkylsulfones, C^ .Q alkylsulfoxides, C3.-10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_6 alkyl, halogen, C-|_6 alkylamino, C-μβ dialkylamino, C3.10 cycloalkyl;
R15 is hydrogen; or is C<|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-|_6 alkylamino, C<|_6 dialkylamino, Cβ-io ary'. cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-μβ alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-|.β alkylamino, C-\ .Q dialkylamino, C-|_6 alkyloxy, C-|.β alkylsulfides, C-|_6 alkylsulfones, C<\_Q alkylsulfoxides, C3.10 cycloalkyl, Ci_g alkyl, halogen; or is C6_-|o heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-|_β alkylamino, C-μβ dialkylamino, C-|_6 alkyloxy, C-|.β alkylsulfides, C-|_6 alkylsulfones, C-|.β alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-\ .Q alkyl, halogen, C-|_6 alkylamino, C-|_6 dialkylamino, C3.10 cycloalkyl;
R16 is hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-|.β alkylamino, C-|_6 dialkylamino, Cβ-io ary'- cyano, nitro; or is C3_io cycloalkyl optionally substituted by groups selected from halogen, C-] _Q alkyl; or is C6_io ary' optionally substituted by groups selected from amino, C-|.g alkylamino, C-μg dialkylamino, C-|_β alkyloxy, C-|_6 alkylsulfides, C<|_6 alkylsulfones, C-|.6 alkylsulfoxides, C3.10 cycloalkyl, C-|.β alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-] _β alkyl, C2-6 alkenyl, halogen, C-μβ alkylamino, C-|_6 dialkylamino, C-|_6 alkyloxy, C-|.Q alkylsulfides, C-] .Q alkylsulfones, C<|_6 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_β alkyl, halogen, C-|_β alkylamino, C-|_6 dialkylamino, C3.10 cycloalkyl; Ri7 is Ri8 or -G3Ri9;
G3 is -O-, -C(O)-, -S-, -S=O, -S(O)2-, C(O)N(RZO)., -N(R21 )C(O)- , -N(R22JS(O)2-, -N(R2S)-; o is O to 3; R18 is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C^.g alkylamino, C-μg dialkylamino, Cg.10 aryl, cyano, nitro; or is C2-6 alkenyl; or is halogen; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C^ _g alkyl; or is Cs-10 aryl optionally substituted by groups selected from amino, C-] _Q alkylamino, C-μg dialkylamino, C-|_g alkyloxy, C-|_g alkylsulfides, C-|_g alkylsulfones, C1.5 alkylsulfoxides, C3.10 cycloalkyl, C-|_g alkyl, halogen; or is CQ.10 heteroaryl optionally substituted by groups selected from C-|_g alkyl,
C2-6 alkenyl, halogen, C-μg alkylamino, C-μg dialkylamino, C-|_g alkyloxy, C-|_g alkylsulfides, C-|_6 alkylsulfones, C-|_g alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_g alkyl, halogen, C-|_6 alkylamino, C-μg dialkylamino, C3.10 cycloalkyl; or is hydroxyl; or is carboxylic acid; or is cyano; or is nitro;
R19 is hydrogen; or is C-|_5 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-|.β alkylamino, C-j.g dialkylamino, Cg. -| Q a|7l. cyano, nitro; or is C3_io cycloalkyl optionally substituted by groups selected from halogen, C-| .Q alkyl; or is Cg.10 aryl optionally substituted by groups selected from amino, C-|_g alkylamino, C-|.g dialkylamino, C-|.g alkyloxy, C-μg alkylsulfides, C-μg alkylsulfones, C-|.g alkylsulfoxides, C3.-10 cycloalkyl, C-|.g alkyl, halogen; or is Cg.10 heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-g alkenyl, halogen, C-μg alkylamino, C-μg dialkylamino, C-|.g alkyloxy, C-|.g alkylsulfides, C-|.g alkylsulfones, C-μg alkylsulfoxides, C3.-10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|.g alkyl, halogen, C-|.g alkylamino, C-|.g dialkylamino, C3.10 cycloalkyl;
R20 js hydrogen; or is C-|_g alkyl optionally substituted by groups selected from halogen, C3_-| Q cycloalkyl, amino, Ci_g alkylamino, C-|.g dialkylamino, Cg. -| Q aryl, cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-μg alkyl; or is C5.-10 aryl optionally substituted by groups selected from amino, C-|_β alkylamino, C-μø dialkylamino, C-1.5 alkyloxy, C-|_e alkylsulfides, C-μβ alkylsulfones, C<|_6 alkylsulfoxides, C3.10 cycloalkyl, C-|_6 alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-μβ alkylamino, C-|_6 dialkylamino, C-|_6 alkyloxy, C-|_e alkylsulfides, C-| .Q alkylsulfones, C-|_6 alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_6 alkyl, halogen, C-|_6 alkylamino, C-|_6 dialkylamino, C3.-10 cycloalkyl;
R21 is hydrogen; or is C-| _β alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-|_6 alkylamino, C-|_6 dialkylamino, Cg-io ary'. cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-μβ alkyl; or is Cβ-io ary' optionally substituted by groups selected from amino, C-|.g alkylamino, C-\ .Q dialkylamino, C-\.Q alkyloxy, C-|_6 alkylsulfides, C-\ .Q alkylsulfones, C-|_g alkylsulfoxides, C3.10 cycloalkyl, C1.6 alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-μg alkylamino, C-μg dialkylamino, C-|.β alkyloxy, C-μg alkylsulfides, C-μs alkylsulfones, C-i.β alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|.β alkyl, halogen, C-|.β alkylamino, C-|_6 dialkylamino, C3.10 cycloalkyl;
R22 js hydrogen; or is C-|_6 alkyl optionally substituted by groups selected from halogen, C3.10 cycloalkyl, amino, C-μø alkylamino, C-|_6 dialkylamino, Cβ-io aryl, cyano, nitro; or is C3.-10 cycloalkyl optionally substituted by groups selected from halogen, C-] _β alkyl; or is Cβ-io aryl optionally substituted by groups selected from amino, C-] _β alkylamino, C-|_6 dialkylamino, C-|_β alkyloxy, Ci_ρ alkylsulfides, C-|_6 alkylsulfones, C-|.β alkylsulfoxides, C3.10 cycloalkyl, C-|_6 alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-|_s alkyl. C2-6 alkenyl, halogen, C-|.β alkylamino, C-|_6 dialkylamino, C-μβ alkyloxy, C-j.g alkylsulfides, C-|.β alkylsulfones, C-μg alkylsulfoxides, C3.10 cycloalkyl, or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|_g alkyl, halogen, C-|_6 alkylamino, C-μg dialkylamino, C3.10 cycloalkyl;
R23 is hydrogen; or is C-| .6 alkyl optionally substituted by groups selected from halogen, C3_io cycloalkyl, amino, C-μg alkylamino, C-μg dialkylamino, Cg.10 aryl, cyano, nitro; or is C3.10 cycloalkyl optionally substituted by groups selected from halogen, C-] .Q alkyl; or is Cg-io aryl optionally substituted by groups selected from amino, C-|_β alkylamino, C-|_6 dialkylamino, C-|_6 alkyloxy, C-|_β alkylsulfides, C-μg alkylsulfones, C-|.β alkylsulfoxides, C3.10 cycloalkyl, C<|_6 alkyl, halogen; or is Cβ-io heteroaryl optionally substituted by groups selected from C-μg alkyl, C2-6 alkenyl, halogen, C-μg alkylamino, C-|_6 dialkylamino, C-|_β alkyloxy, C1.6 alkylsulfides, C-μg alkylsulfones, C-μg alkylsulfoxides, C3.10 cycloalkyl; or is 3-10 ring member non-aromatic heterocycle optionally substituted by groups selected from C-|.g alkyl, halogen, C-|_6 alkylamino, C<\_Q dialkylamino, C3.10 cycloalkyl.
2. A compound according to claim 1 , wherein the configuration at the asymmetric carbon atom, is in the "S" configuration according to formula Ia such as:
Figure imgf000041_0001
FT formula Ia
3. A compound according to claim 1 and 2 wherein X is CH; and W is N; and R^ is chlorine; and R is chlorine; and R^ is C-|.β alkyl; and n is 0; and m is 0; and o is 0; and Y1 is CH; and Y2 is CH; and Y3 is CH; and Y^ is CH and Y5 is CH.
4. (2S)-3-[2-(2,6-dichlorophenyl)quinolin-6-yl]-2-{[methyl(phenyl) carbamoyl]amino} propanoic acid.
5. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to any one of claims 1 to 4 and a pharmaceutically acceptable adjuvant, diluent or carrier.
6. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to any one of claims 1 to 4 for use as a medicine.
7. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to any one of claims 1 to 4 in the manufacture of a medicament.
8. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a compound according to any claims 1 to 4 in the manufacture of a medicament for the treatment of α4 dependent inflammatory or medical conditions.
9. Use of a compound according to any one of claims 1 to 4 for the manufacture of a medicament for the treatment of asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, α4-related cancers such as lung e.g. non-small cell lung, pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer.
10. Compound according to any one of claims 1 to 4 for use as a medicament.
11. Compound according to any one of claims 1 to 4 for curing asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders including dermatitis, psoriasis, urticaria, pruritus and eczema, rheumatoid arthritis, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, multiple sclerosis and other autoimmune disorders, acute myelogenous leukaemia, transplantation and atherosclerosis, transplant rejection, α4-related cancers such as lung e.g. non-small cell lung, pancreatic, prostate, renal, cervical, ovarian, colorectal, mammary carcinoma, endometrial, bladder, malignant melanoma, seminomas, thyroid, acute myelogenous leukaemia and gastric cancer.
PCT/EP2008/003839 2007-05-14 2008-05-13 Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses WO2008138592A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0709218.2 2007-05-14
GB0709218A GB0709218D0 (en) 2007-05-14 2007-05-14 Bicycle and heterobicyclic derivatives, proccesses for preparing them and their uses
EP07012329.4 2007-06-23
EP07012329 2007-06-23

Publications (1)

Publication Number Publication Date
WO2008138592A1 true WO2008138592A1 (en) 2008-11-20

Family

ID=39531352

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/003839 WO2008138592A1 (en) 2007-05-14 2008-05-13 Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses

Country Status (1)

Country Link
WO (1) WO2008138592A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247071B2 (en) 2016-12-21 2025-03-11 Amgen Inc. Anti-TNF alpha antibody formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093237A1 (en) * 2002-04-30 2003-11-13 Ucb, S.A. 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
EP1477482A1 (en) * 2002-02-20 2004-11-17 Ajinomoto Co., Inc. Novel phenylalanine derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1477482A1 (en) * 2002-02-20 2004-11-17 Ajinomoto Co., Inc. Novel phenylalanine derivative
WO2003093237A1 (en) * 2002-04-30 2003-11-13 Ucb, S.A. 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247071B2 (en) 2016-12-21 2025-03-11 Amgen Inc. Anti-TNF alpha antibody formulations

Similar Documents

Publication Publication Date Title
US7732614B2 (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
US10000489B2 (en) Compounds αvβ6 integrin antagonists
EP0385237B1 (en) 2-(1-piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same
CA2395846C (en) Diazepan derivatives or salts thereof
US6423711B1 (en) Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands
EA007983B1 (en) Indolizines as kinase protein inhibitors
KR20140040774A (en) Imidazopyridine compound
AU2008310874A1 (en) Heterocyclic compounds as CRTH2 receptor antagonists
US20020156280A1 (en) Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
WO2008125210A1 (en) Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases
WO2008064823A1 (en) Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008138591A2 (en) Bicyclic and heterobicyclic derivatives,processes for preparing them and their uses
KR20010102544A (en) Carbamoyl Tetrahydropyridine Derivatives
WO2008138592A1 (en) Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008138615A1 (en) Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2008125215A1 (en) Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
WO2001017959A2 (en) Vitronectin receptor antagonists
JP3786983B2 (en) Pyrrolidinone derivative
JP2007277093A (en) Tricyclic compound
SK137597A3 (en) 1-£&#39;omega&#39;-(3,4-dihydro-2-naphthalenyl)alkyl| cyclic amine derivatives, process for producing the same, and medicinal composition containing the same
CN101193883A (en) 2,6 quinolinyl derivatives, their preparation process and their use as medicine
US20090143429A1 (en) Quinoline Derivatives as Neurokinin Receptor Antagonists
US20080096885A1 (en) Quinoline Derivatives as Neurokinin Receptor Antagonists
ES2359935T3 (en) DERIVATIVES OF 2,6-QUINOLINILO, PROCEDURES TO PREPARE THEM AND THEIR USE AS A MEDICINAL PRODUCT.
WO2017107877A1 (en) Biphenyl derivative and preparation method and medical use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08749447

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08749447

Country of ref document: EP

Kind code of ref document: A1